CagriSema Beat Semaglutide. By How Much?

CagriSema — semaglutide combined with cagrilintide — met its endpoint against semaglutide alone in people with type 2 diabetes, and the result is being reported as superiority. It is superiority. The margin is 0.16 percentage points of HbA1c, and adverse events were more common in the combination group.^[1]

What was actually measured

REIMAGINE 2 compared CagriSema against semaglutide and against cagrilintide alone in adults with type 2 diabetes already taking metformin, with or without an SGLT2 inhibitor. The endpoint was HbA1c — blood sugar control, not weight.

So the combination lowered HbA1c by about a sixth of a percentage point more than semaglutide alone, while roughly six more people in every hundred reported an adverse event. Gastrointestinal effects were the most common in every active group.^[1]

Why 'superior' is a technical word

In trial language, superiority means the confidence interval excludes zero in the right direction. It carries no information about size. A large enough trial can establish superiority for a difference too small for any patient to notice, and that is roughly what happened here.

Statistical significance answers “is it real?”. It never answers “is it enough?”.

Whether 0.16 points of HbA1c matters depends entirely on where you are starting. For someone close to target it is negligible. For someone far above it, on a drug they already tolerate, it is still unlikely to be the deciding factor — and the extra adverse events sit on the other side of that scale.

What the combination is trying to do

Cagrilintide is an amylin analog, a different mechanism from a GLP-1, and the logic of combining them is the same logic behind pairing drugs in oncology or hypertension: two pathways, additive effect, potentially lower doses of each. It is a reasonable strategy and the field is clearly moving toward it — see also bimagrumab plus semaglutide.

One thing worth noting for this register specifically: cagrilintide is on the FDA’s list of molecules that cannot lawfully be used in compounding. Anything offering a CagriSema-style combination outside a trial is not a preview of the future; it is that.